We collaborate with Genentech, a member of the Roche Group, on the development and commercialisation of rituximab. In addition, in the United States we collaborate with Genentech on obinutuzumab. The Roche Group maintains sole responsibility for the development, manufacturing and commercialisation of rituximab and obinutuzumab in the U.S.